IfosfamideThird Party Manufacturing in India

Ifosfamide is a cytotoxic alkylating agent belonging to the oxazaphosphorine class, structurally related to cyclophosphamide. It acts as a prodrug that requires metabolic activation by hepatic cytochrome P450 enzymes, primarily CYP3A4 and CYP2B6, to generate active metabolites including isophosphoramide mustard and acrolein through hydroxylation at the ring carbon atom. Isophosphoramide mustard alkylates DNA by forming covalent bonds at guanine N-7 positions, creating interstrand and intrastrand DNA crosslinks that prevent DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells. The secondary metabolite acrolein contributes to cytotoxicity but is also responsible for urotoxicity, which is why ifosfamide is almost always administered with mesna as a uroprotective agent. Unlike some cell-cycle specific chemotherapy agents, ifosfamide's alkylating activity affects cells at all stages of the cell cycle. It demonstrates particularly good antitumor activity against a wide range of solid tumors and hematological malignancies, with selectivity partly due to the higher metabolic rate and reduced DNA repair capacity of malignant cells compared to normal tissues.

Therapeutic Uses

Ifosfamide is prescribed for the treatment of:

• Germ Cell Testicular Cancer: As third-line chemotherapy in combination with other antineoplastic agents for patients with refractory disease.
• Soft Tissue Sarcomas: Used as first-line single agent therapy and in combination regimens, showing objective response rates of approximately 40%.
• Ewing Sarcoma: High-dose ifosfamide is more effective than standard regimens for recurrent or refractory cases.
• Non-Hodgkin and Hodgkin Lymphoma: Used as salvage therapy for Burkitt lymphoma, diffuse large B-cell lymphoma, and relapsed Hodgkin lymphoma as part of the RICE regimen.
• Osteosarcoma: Effective as standalone high-dose treatment for refractory or recurrent cases.
• Lung Cancer: Provides benefits as maintenance or consolidation therapy in small-cell and non-small-cell lung cancer.
• Cervical and Ovarian Cancer: Used in advanced or recurrent disease, often in combination with platinum-based agents.
• Bladder Carcinoma: Used in advanced cases.

Why Manufacturers Choose Ifosfamide

Ifosfamide remains a cornerstone of many chemotherapy regimens due to its broad-spectrum antineoplastic activity and established efficacy across multiple cancer types. It is a high-value oncology molecule with consistent demand from hospital supply chains and cancer treatment centers. With the mandatory co-administration of mesna allowing safer use, ifosfamide continues to be widely prescribed in both adjuvant and palliative settings.

This makes Ifosfamide a sought-after cytotoxic agent for third party manufacturing in India, with steady demand from domestic oncology hospitals and export-oriented pharmaceutical companies supplying to regulated markets.